Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGA: Aflibercept in Neovascular Glaucoma
NCT02396316Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2015
- Primary completion
- Jun 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in neovascular glaucoma (NVG) (2 arms), sponsored by Bayer. Primary endpoint: Change in Intraocular Pressure From Baseline at 1 week. Started Apr 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on NCT02396316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02396316.